EANS-News: SYGNIS Pharma AG
SYGNIS is granted the European and US patent for a
very versatile and efficient drug screening platform
15.01.2013 – 11:04
-------------------------------------------------------------------------------- Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- Patents, Copyright & Trademarks Heidelberg (euro adhoc) - Press Release SYGNIS is granted the European and US patent for a very versatile and efficient drug screening platform - The patents protect a new procedure for screening and characterizing drugs in development, based on detection of protein-protein interactions - Detection of protein-protein interaction is becoming increasingly important for developing new drugs as such technologies can simplify assays and enable screening for new drugs with a fully novel approach - SYGNIS' new technology broadens the possibilities for obtaining novel drugs - SYGNIS intends to license the new technology to a distribution partner - SYGNIS concluded its merger with the Spanish company X-Pol, a member of the GENETRIX Group, in December last year Heidelberg, 15 January 2013 - The biotech company SYGNIS Pharma AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) has been granted the European and US patent for a new basic technology for the detection of protein-protein interactions, a screening platform for the development of novel drugs. In the words of SYGNIS' CEO, Pilar de la Huerta, "the technology will be licensed to a distribution partner and we expect to see our first revenues during the current financial year 2013." Protein-protein interactions falls within the scope of proteomics, a field that is growing in importance for research into new customized drugs. SYGNIS' new platform can be used to improve the characterization of new drugs in development and identification of new therapeutic targets. SYGNIS' technology will increase the potential for generating better drugs within the customized drug development field. Following its merger with the Spanish company X-Pol, which forms part of the GENETRIX Group, SYGNIS aims to become a key player in the growing market for molecular tools and personalized medicine. SYGNIS aims to use these patents, together with its recent company restructuring and successful implementation of the polymerase QualiPhiTM, to enhance the impetus it announced on its merger with X-Pol and become a prominent player in the growing market for new DNA tools and customized drugs, a sector that has seen a two-digit growth rate over the last few years. According to sources from SYGNIS, this transformation will enable it to obtain its first revenues in 2013 and operating profit in successive years. For further information please contact: Peter Willinger CFO SYGNIS Pharma AG Tel.: +49 6221 454 836 E-mail: peter.willinger@sygnis.de About SYGNIS Pharma AG: www.sygnis.de SYGNIS Pharma AG (Heidelberg, Germany) is a biotech company listed in the Prime Standard of the German Stock Exchange (Ticker: LIO1; ISIN: DE000A1RFM03). According to the 2012 newly defined business strategy, the Company focuses on the development and marketing of novel technologies in molecular biology, e.g. in the field of DNA amplification and sequencing. For the key product "QualiPhiTM", an improved polymerase for amplifying DNA, an exclusive worldwide license has been granted to Qiagen. ### Disclaimer Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ### Further inquiry note: Michael Wolf Telefon: +49 (6221) 454 - 6 E-Mail: Michael.Wolf@sygnis.de end of announcement euro adhoc -------------------------------------------------------------------------------- company: SYGNIS Pharma AG Im Neuenheimer Feld 515 D-69120 Heidelberg phone: +49 (0)6221 454-6 FAX: +49 (0)6221 454-777 mail: contact@sygnis.de WWW: http://www.sygnis.de sector: Biotechnology ISIN: DE000A1RFM03 indexes: CDAX, Prime All Share stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf, Stuttgart, regulated dealing/prime standard: Frankfurt language: English